- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02568267
Mandstudie van entrectinib (RXDX-101) voor de behandeling van patiënten met solide tumoren met NTRK 1/2/3 (Trk A/B/C), ROS1 of ALK genherschikkingen (fusies) (STARTRK-2)
Een open-label, multicenter, wereldwijde fase 2-basketstudie van entrectinib voor de behandeling van patiënten met lokaal gevorderde of gemetastaseerde vaste tumoren met NTRK1/2/3-, ROS1- of ALK-genherschikkingen
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Studie Overzicht
Toestand
Conditie
- Melanoma
- Niercelcarcinoom
- Volwassen solide tumor
- Borstkanker
- Hoofd- en nekneoplasmata
- Colorectale kanker
- Alvleesklierkanker
- Eierstokkanker
- Niet-kleincellige longkanker
- Neuro-endocriene tumoren
- Lymfoom, grootcellig, anaplastisch
- Cholangiocarcinoom
- Papillaire schildklierkanker
- Sarcomen
- Speekselklierkanker
- Primaire hersentumoren
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Uitgebreide toegang
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Liverpool, New South Wales, Australië, 2170
- Liverpool Hospital
-
Newcastle, New South Wales, Australië, 2305
- Newcastle Private Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australië, 5042
- Flinders Medical Centre
-
-
Victoria
-
Heidelberg, Victoria, Australië, 3084
- Austin Health
-
-
-
-
-
Edegem, België, 2650
- Pharmacy
-
-
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Guangzhou, China, 528400
- Cancer Center of Guangzhou Medical University
-
Hangzhou, China, 310022
- Zhejiang Cancer Hospital
-
Shanghai, China, 200120
- Fudan University Shanghai Cancer Center
-
Shanghai, China, 200030
- Shanghai chest hospital
-
Shenzhen, China, 510852
- Shenzhen People's Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430023
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Sichuan Cancer Hospital
-
-
-
-
-
Berlin, Duitsland, 13125
- Evang. Lungenklinik Berlin Klinik für Pneumologie
-
Cologne, Duitsland, 50937
- Universitaetsklinikum Koeln
-
Göttingen, Duitsland, 37075
- Universitaetsmedizin Goettingen
-
Heidelberg, Duitsland, 69120
- NCT Uniklinikum Heidelberg
-
-
-
-
-
Angers, Frankrijk, 49055
- Institut de Cancerologie de l Ouest
-
Lyon, Frankrijk, 69373
- Centre Leon Berard
-
Marseille, Frankrijk, 13915
- Hôpital Nord - AP-HM Marseille#
-
Marseille, Frankrijk, 13385
- Hôpital de la Timone
-
Montpellier, Frankrijk, 34090
- Institut de Recherche en Cancérologie de Montpellier
-
Toulouse, Frankrijk, 31059
- Institut Claudius Regaud
-
Villejuif, Frankrijk, 94805
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hongkong
- The University of Hong Kong
-
Hong Kong, Hongkong
- Princess Margaret Hospital
-
Kowloon, Hongkong
- Queen Elizabeth Hospital
-
Shatin, Hongkong, 123456
- The Chinese University of Hong Kong
-
-
-
-
Campania
-
Naples, Campania, Italië, 80131
- Seconda Università degli Studi di Napoli
-
-
Lazio
-
Rome, Lazio, Italië, 128
- Università Campus Bio-Medico di Roma
-
-
Lombardy
-
Milan, Lombardy, Italië, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Lombardy, Italië, 20162
- Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
-
-
Tuscany
-
Pisa, Tuscany, Italië, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
Umbria
-
Perugia, Umbria, Italië, 6132
- Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
-
-
Veneto
-
Padova, Veneto, Italië, 35128
- IOV - Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Chūō, Japan, 104-0045
- National Cancer Center Hospital
-
Hyōgo, Japan, 673-8558
- Hyogo Cancer Center, Dept of Respiratory Medicine
-
Matsuyama, Japan, 791-0280
- NHO Shikoku Cancer Center
-
Miyagi, Japan, 981-1293
- Miyagi Cancer Center
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Osaka, Japan, 534-0021
- Osaka City General Hospital
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Leiden, Nederland, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
Gliwice, Polen, 44-101
- Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
-
Późna, Polen, 60-569
- Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego
-
-
-
-
-
Singapore, Singapore, 119228
- National University Hospital
-
Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
-
-
-
-
Barcelona, Spanje, 08035
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona
-
Madrid, Spanje, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanje, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spanje, 28046
- Hospital Universitario La Paz
-
Madrid, Spanje, 28040
- Hospital Universitario Clínico San Carlos
-
Málaga, Spanje, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Spanje, 41013
- Hospital Universitario Virgen del Rocio
-
-
Madrid
-
Fuenlabrada, Madrid, Spanje, 28942
- Centro Nacional de Investigaciones Oncológicas(CNIO)
-
-
-
-
-
Tainan, Taiwan, 70457
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 00100
- National Taiwan University Hospital
-
-
-
-
-
Cambridge, Verenigd Koninkrijk, CB2 0QQ
- Addenbrookes Hospital
-
London, Verenigd Koninkrijk, W1G 6AD
- Sarah Cannon Research Institute
-
Manchester, Verenigd Koninkrijk, M20 4BX
- The Christie
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Mayo Clinic
-
Phoenix, Arizona, Verenigde Staten, 85013
- Dignity Health St Joseph's Hospital and Medical Center
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Cancer Center
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services
-
La Jolla, California, Verenigde Staten, 92037
- Scripps Clinic
-
La Jolla, California, Verenigde Staten, 92093
- University of California San Diego Moores Cancer Center
-
Los Angeles, California, Verenigde Staten, 90027
- Southern California Kaiser Permanente
-
Orange, California, Verenigde Staten, 92868
- Univ Of California Irvine College Of Medicine
-
San Francisco, California, Verenigde Staten, 94158
- UCSF Mission Bay
-
San Francisco, California, Verenigde Staten, 94115
- UCSF Mount Zion Medical Ctr
-
Santa Monica, California, Verenigde Staten, 90403
- Sarcoma Oncology Center
-
Santa Monica, California, Verenigde Staten, 90403
- Sarcoma Oncology Research Center LLC
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 6519
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20007
- Georgetown University Medical Center Lombardi Cancer Center
-
-
Florida
-
Sarasota, Florida, Verenigde Staten, 34232
- Florida Cancer Specialists - Sarasota
-
Tampa, Florida, Verenigde Staten, 33612-9497
- Moffitt Cancer Center
-
Tampa, Florida, Verenigde Staten, 33612-9497
- H. Lee Moffitt Cancer Center and Research Inst.
-
-
Georgia
-
Athens, Georgia, Verenigde Staten, 30607
- University Cancer & Blood Center, LLC
-
Atlanta, Georgia, Verenigde Staten, 30322
- Winship Cancer Institute
-
Newnan, Georgia, Verenigde Staten, 30265
- Southeastern Regional Medical Center, Inc.
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology
-
Zion, Illinois, Verenigde Staten, 60099
- Midwestern Regional Medical Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21237
- Weinberg Cancer Institution at Franklin Square
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana Farber Cancer Institute
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hosp CAR
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Verenigde Staten, 48201
- Karmanos Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- Regents of the University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63128
- Washington University
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89169
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
-
-
New York
-
East Setauket, New York, Verenigde Staten, 11733
- North Shore Hem Onc Associates
-
New York, New York, Verenigde Staten, 10022
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Levine Cancer Institute
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Atrium Health Levine Cancer Institute
-
Durham, North Carolina, Verenigde Staten, 27710
- Duke Cancer Institute
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239-3098
- Oregon Health & Science University
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health & Science Univ
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75230
- Mary Crowley Medical Research Center
-
Temple, Texas, Verenigde Staten, 76508
- Baylor Scott & White Health
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Virginia Cancer Specialists, PC
-
Norfolk, Virginia, Verenigde Staten, 23502
- Virginia Oncology Associates - Hampton
-
-
-
-
-
Seoul, Zuid -Korea, 03080
- Seoul National University Hospital
-
Seoul, Zuid -Korea, 06351
- Samsung Medical Center
-
Seoul, Zuid -Korea, 05505
- Asan Medical Center.
-
Seoul, Zuid -Korea, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
-
For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment
-
Measurable or evaluable disease
-
Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed
-
Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy
-
At least 4 weeks must have elapsed since completion of antibody-directed therapy
-
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks
-
Adequate organ function as defined per protocol
-
Ability to swallow entrectinib intact
-
Other protocol specified criteria
Exclusion Criteria:
-
Current participation in another therapeutic clinical trial
-
Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.
-
History of other previous cancer that would interfere with the determination of safety or efficacy
-
Familial or personal history of congenital bone disorders, or bone metabolism alterations
-
Incomplete recovery from any surgery
-
History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤50% observed during screening for the study
-
History of non-pharmacologically induced prolonged QTc interval
-
History of additional risk factors for torsades de pointes
-
Peripheral neuropathy Grade ≥ 2
-
Known active infections
-
Active gastrointestinal disease or other malabsorption syndromes
-
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
-
Other protocol specified criteria
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: NTRK1/2/3-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ROS1-rearranged NSCLC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ALK- or ROS1-rearranged NSCLC
with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: NTRK/1/2/3-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ROS1-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ALK-rearranged mCRC
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: NTRK1/2/3-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ROS1-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
|
Experimenteel: ALK-rearranged other solid tumor
Oral entrectinib (RXDX-101) |
TrkA/B/C, ROS1, and ALK inhibitor
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Duration of Response
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Time to Response
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Clinical Benefit Rate
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RECIST v1.1 |
Approximately 24 months
|
|
Intracranial Tumor Response
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
CNS Progression-free Survival
Tijdsspanne: Approximately 24 months
|
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable |
Approximately 24 months
|
|
Progression-free Survival
Tijdsspanne: Approximately 30 months
|
Assessed by Kaplan-Meier method |
Approximately 30 months
|
|
Overall Survival
Tijdsspanne: Approximately 36 months
|
Assessed by Kaplan-Meier method |
Approximately 36 months
|
|
Population PK
Tijdsspanne: Approximately 24 months
|
Assessed by Kaplan-Meier method |
Approximately 24 months
|
|
Adverse Events
Tijdsspanne: Approximately 36 months
|
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE |
Approximately 36 months
|
|
Quality of Life
Tijdsspanne: Approximately 24 months
|
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively |
Approximately 24 months
|
|
Bone Growth and Bone Mineral Density
Tijdsspanne: Approximately 30 months
|
Assessed with DHA scans |
Approximately 30 months
|
|
Bone Biomarkers
Tijdsspanne: Approximately 30 months
|
Measured by blood |
Approximately 30 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trials, Hoffmann-La Roche
Publicaties en nuttige links
Algemene publicaties
- Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.
- Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
- Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.
- Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.
- Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
- Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 Jun;8:e2300721. doi: 10.1200/PO.23.00721.
- Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series. Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.
- Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.
- Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Colorectale kanker
- Niet-kleincellige longkanker
- Borstkanker
- Eierstokkanker
- Melanoma
- Alvleesklierkanker
- Cholangiocarcinoom
- Neuro-endocriene tumoren
- Mand studie
- Niercelkanker
- Papillaire schildklierkanker
- ROS1
- ALK
- Primaire hersentumoren
- Sarcomen
- Entrectinib
- RXDX-101
- TrkA
- TrkB
- TrkC
- NTRK1
- NTRK2
- NTRK3
- Trk-fusies
- NTRK-genherschikkingen
- ROS1-fusies
- Herschikkingen van ROS1-genen
- ALK-fusies
- ALK-genherschikkingen
- Speekselklierkanker
- Hoofd- en nekkanker
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Mondziekten
- Stomatognatische ziekten
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Darmziekten
- Ziekten van het immuunsysteem
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Intestinale neoplasmata
- Rectale ziekten
- Genitale ziekten, vrouw
- Longziekten
- Schildklier neoplasmata
- Endocriene klierneoplasmata
- Alvleesklier Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Colon Ziekten
- Longneoplasmata
- Ovariële ziekten
- Adnexale ziekten
- Genitale neoplasmata, vrouwelijk
- Gonadale aandoeningen
- Huidziektes
- Borst ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Urologische neoplasmata
- Carcinoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Lymfoom
- Neoplasmata van het zenuwstelsel
- Nierneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Speekselklierziekten
- Neoplasmata, bindweefsel en zacht weefsel
- Nevi en melanomen
- Huidneoplasmata
- Neoplasmata van het centrale zenuwstelsel
- Schildklier Ziekten
- Adenocarcinoom, Papillair
- Mond neoplasmata
- Lymfoom, T-cel
- Huid- en bindweefselaandoeningen
- Hemische en lymfatische ziekten
- Schildklierkanker, Papillair
- Colorectale neoplasmata
- Ovariumneoplasmata
- Borstneoplasmata
- Pancreasneoplasmata
- Carcinoom, niercel
- Carcinoom, niet-kleincellige long
- Cholangiocarcinoom
- Hoofd- en nekneoplasmata
- Neuro-endocriene tumoren
- Melanoma
- Sarcoom
- Lymfoom, grootcellig, anaplastisch
- Hersenneoplasmata
- Speekselklierneoplasmata
- entrectinib
Andere studie-ID-nummers
- RXDX-101-02
- 2015-003385-84 (EudraCT-nummer)
- GO40782 (Andere identificatie: Hoffman-La Roche)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
- 2015 (Subsidie/contract van de Amerikaanse NIH)
- 2023-505034-10-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .